{"id":"NCT01262365","sponsor":"UCB Pharma","briefTitle":"Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2010-12-17","resultsPosted":"2018-06-29","lastUpdate":"2018-09-28"},"enrollment":793,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Systemic Lupus Erythematosus"],"interventions":[{"type":"DRUG","name":"Epratuzumab","otherNames":[]},{"type":"DRUG","name":"Epratuzumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo (Weekly infusion)","type":"PLACEBO_COMPARATOR"},{"label":"Epratuzumab 600 mg per week","type":"EXPERIMENTAL"},{"label":"Epratuzumab 1200 mg every other week","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus Erythematosus (SLE)","primaryOutcome":{"measure":"The Percent of Subjects Meeting Treatment Response Criteria at Week 48 According to a Combined Response Index","timeFrame":"At Week 48","effectByArm":[{"arm":"Placebo (Weekly Infusion) FAS","deltaMin":34.1,"sd":null},{"arm":"Epratuzumab 1200 mg Every Other Week (FAS)","deltaMin":39.8,"sd":null},{"arm":"Epratuzumab 600 mg Per Week (FAS)","deltaMin":37.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.175"},{"comp":"OG000 vs OG002","p":"=0.442"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":141,"countries":["United States","Australia","Belgium","Brazil","Bulgaria","Czechia","Estonia","France","Germany","India","Israel","Italy","Lithuania","Mexico","Puerto Rico","Romania","Russia","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["29381843","27598855"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":48,"n":263},"commonTop":["Headache","Upper respiratory tract infection","Nausea","Urinary tract infection","Nasopharyngitis"]}}